192 related articles for article (PubMed ID: 22517811)
21. Postmenopausal hormone therapy and risk of idiopathic venous thromboembolism: results from the E3N cohort study.
Canonico M; Fournier A; Carcaillon L; Olié V; Plu-Bureau G; Oger E; Mesrine S; Boutron-Ruault MC; Clavel-Chapelon F; Scarabin PY
Arterioscler Thromb Vasc Biol; 2010 Feb; 30(2):340-5. PubMed ID: 19834106
[TBL] [Abstract][Full Text] [Related]
22. Risk factors for epithelial borderline ovarian tumors: results of a Swedish case-control study.
Riman T; Dickman PW; Nilsson S; Correia N; Nordlinder H; Magnusson CM; Persson IR
Gynecol Oncol; 2001 Dec; 83(3):575-85. PubMed ID: 11733975
[TBL] [Abstract][Full Text] [Related]
23. Postmenopausal hormone replacement therapy and risk of acute pancreatitis: a population-based case-control study.
Tetsche MS; Jacobsen J; Nørgaard M; Baron JA; Sørensen HT
Am J Gastroenterol; 2007 Feb; 102(2):275-8. PubMed ID: 17311649
[TBL] [Abstract][Full Text] [Related]
24. Cancer incidence and mortality in women receiving estrogen and estrogen-progestin replacement therapy--long-term follow-up of a Swedish cohort.
Persson I; Yuen J; Bergkvist L; Schairer C
Int J Cancer; 1996 Jul; 67(3):327-32. PubMed ID: 8707404
[TBL] [Abstract][Full Text] [Related]
25. Prophylactic Oophorectomy: Reducing the U.S. Death Rate from Epithelial Ovarian Cancer. A Continuing Debate.
Piver MS
Oncologist; 1996; 1(5):326-330. PubMed ID: 10388011
[TBL] [Abstract][Full Text] [Related]
26. Estrogen replacement therapy and ovarian cancer.
Folsom AR; Anderson JP; Ross JA
Epidemiology; 2004 Jan; 15(1):100-4. PubMed ID: 14712153
[TBL] [Abstract][Full Text] [Related]
27. Increased risk of stroke in hypertensive women using hormone therapy: analyses based on the Danish Nurse Study.
Løkkegaard E; Jovanovic Z; Heitmann BL; Keiding N; Ottesen B; Hundrup YA; Obel EB; Pedersen AT
Arch Neurol; 2003 Oct; 60(10):1379-84. PubMed ID: 14568807
[TBL] [Abstract][Full Text] [Related]
28. Mortality rates among early-stage hormone receptor-positive breast cancer patients: a population-based cohort study in Denmark.
Christiansen P; Bjerre K; Ejlertsen B; Jensen MB; Rasmussen BB; Lænkholm AV; Kroman N; Ewertz M; Offersen B; Toftdahl DB; Møller S; Mouridsen HT;
J Natl Cancer Inst; 2011 Sep; 103(18):1363-72. PubMed ID: 21881042
[TBL] [Abstract][Full Text] [Related]
29. Prior hormone therapy and breast cancer risk in the Women's Health Initiative randomized trial of estrogen plus progestin.
Anderson GL; Chlebowski RT; Rossouw JE; Rodabough RJ; McTiernan A; Margolis KL; Aggerwal A; David Curb J; Hendrix SL; Allan Hubbell F; Khandekar J; Lane DS; Lasser N; Lopez AM; Potter J; Ritenbaugh C
Maturitas; 2006 Sep; 55(2):103-15. PubMed ID: 16815651
[TBL] [Abstract][Full Text] [Related]
30. Hormone replacement therapy and endometrial cancer risk: a meta-analysis.
Grady D; Gebretsadik T; Kerlikowske K; Ernster V; Petitti D
Obstet Gynecol; 1995 Feb; 85(2):304-13. PubMed ID: 7824251
[TBL] [Abstract][Full Text] [Related]
31. Hormone replacement therapy in Denmark, 1995-2004.
Løkkegaard E; Lidegaard O; Møller LN; Agger C; Andreasen AH; Jørgensen T
Acta Obstet Gynecol Scand; 2007; 86(11):1342-51. PubMed ID: 17963062
[TBL] [Abstract][Full Text] [Related]
32. Hormone replacement therapy containing progestins and given continuously increases breast carcinoma risk in Sweden.
Olsson HL; Ingvar C; Bladström A
Cancer; 2003 Mar; 97(6):1387-92. PubMed ID: 12627501
[TBL] [Abstract][Full Text] [Related]
33. Hyperestrogenism: a relevant risk factor for the development of cancer from endometriosis.
Zanetta GM; Webb MJ; Li H; Keeney GL
Gynecol Oncol; 2000 Oct; 79(1):18-22. PubMed ID: 11006024
[TBL] [Abstract][Full Text] [Related]
34. Cancer issues.
Marsden J; Sturdee D
Best Pract Res Clin Obstet Gynaecol; 2009 Feb; 23(1):87-107. PubMed ID: 19036643
[TBL] [Abstract][Full Text] [Related]
35. The influence of hormone therapies on colon and rectal cancer.
Mørch LS; Lidegaard Ø; Keiding N; Løkkegaard E; Kjær SK
Eur J Epidemiol; 2016 May; 31(5):481-9. PubMed ID: 26758900
[TBL] [Abstract][Full Text] [Related]
36. Noncontraceptive estrogen use and the occurrence of ovarian cancer.
Weiss NS; Lyon JL; Krishnamurthy S; Dietert SE; Liff JM; Daling JR
J Natl Cancer Inst; 1982 Jan; 68(1):95-8. PubMed ID: 6948131
[TBL] [Abstract][Full Text] [Related]
37. Case-control study of postmenopausal hormone replacement therapy and endometrial cancer.
Strom BL; Schinnar R; Weber AL; Bunin G; Berlin JA; Baumgarten M; DeMichele A; Rubin SC; Berlin M; Troxel AB; Rebbeck TR
Am J Epidemiol; 2006 Oct; 164(8):775-86. PubMed ID: 16997897
[TBL] [Abstract][Full Text] [Related]
38. Different risk factor profiles for mucinous and nonmucinous ovarian cancer: results from the Danish MALOVA study.
Soegaard M; Jensen A; Høgdall E; Christensen L; Høgdall C; Blaakaer J; Kjaer SK
Cancer Epidemiol Biomarkers Prev; 2007 Jun; 16(6):1160-6. PubMed ID: 17548679
[TBL] [Abstract][Full Text] [Related]
39. Postmenopausal hormone therapy: cardiovascular risks.
Prescrire Int; 2003 Apr; 12(64):65-9. PubMed ID: 12674130
[TBL] [Abstract][Full Text] [Related]
40. Association of estrogen and progestin potency of oral contraceptives with ovarian carcinoma risk.
Lurie G; Thompson P; McDuffie KE; Carney ME; Terada KY; Goodman MT
Obstet Gynecol; 2007 Mar; 109(3):597-607. PubMed ID: 17329510
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
